Report title: Heidelberg Pharma Holding GmbH & Co KG - Portfolio Company Report
from Thomson Financial Venture Economics
published May 16, 2009

Price $24.00 available for immediate download
Report Overview
 
About Thomson Financial Venture Econ...

Develops therapeutics for the treatment of cancer and HIV. The Company has developed Enhanced Pro-Drug Technology which allows the improvement of potency, tolerability and pharmacokinetic properties of active basic compounds or drugs. Using this technology, Heidelberg Pharma offers design and development of Enhanced Pro-Drugs from basic compounds provided by partners. The resulting Enhanced Pro-Drugs are patentable new chemical entities (NCEs). ; Develops therapeutics for the treatment of cancer and HIV.

Report Type: This research report shows venture capital financing information for this specific company.
Executives Listed: 8
Number of Investing Funds: 2
Free Sample: Click Here to Download
Format:
PDF Adobe Acrobat


Price: $24.00



  Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.